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BACKGROUND: Extracapsular spread (ECS) of lymph node metastasis in head and neck cancers, including oral squamous cell
carcinomas (OSCCs), is known to reflect tumour aggressiveness, and is significantly associated with high rates of loco-regional
recurrence, distant metastasis, and poor outcome. The purpose of this study was to confirm ECS as an important prognostic indicator
and to determine the significant factors associated with ECS in OSCCs.
METHODS: We investigated the incidence of ECS and impact of ECS on survival in 127 OSCC patients. To determine the factors
significantly correlated with ECS, we examined many factors, including the clinicopathological features of primary tumours, lymph
node metastasis, and copy number aberrations of the cyclin D1 gene (CCND1) and epidermal growth factor receptor gene (EGFR)a t
primary tumours, and evaluated the value of predicting the risk of ECS of the metastatic lymph node.
RESULTS: Kaplan–Meier and multivariate disease-free and overall survival analysis clearly demonstrated that ECS is an independent
prognostic factor in OSCCs. Moreover, logistic regression analysis showed that the number of pathologically positive nodes and copy
number aberrations of EGFR at the primary tumour are independent predictors of ECS.
CONCLUSIONS: The findings suggest that ECS is an independent prognostic factor in OSCCs. Moreover, the number of pathologically
positive lymph nodes and EGFR numerical aberrations of the primary tumour were also shown to be excellent predictors of ECS in
OSCCs. Preoperative evaluation of EGFR numerical aberrations might therefore be a useful tool for selecting patients at high risk of
ECS, who would benefit from targeted aggressive multimodality therapy.
British Journal of Cancer (2011) 104, 850–855. doi:10.1038/bjc.2011.22 www.bjcancer.com
Published online 8 February 2011
& 2011 Cancer Research UK
Keywords: extracapsular spread; oral cavity; squamous cell carcinoma; fluorescence in situ hybridisation; lymph node
                                                       
Head and neck squamous cell carcinoma (HNSCC), including oral
cancer, is the sixth most common malignancy in humans.
Despite tremendous improvements in surgery, radiotherapy, and
chemotherapy over the past decade, the prognosis for patients with
HNSCCs has more or less remained unchanged for the past
30 years (Forastiere et al, 2001; Silverman, 2001). This is primarily
because patients continue to die from metastatic disease at
regional and distant sites, although local recurrence and second
primary tumours are also a cause of death in these patients. It is
widely accepted that the presence of metastasis in cervical lymph
nodes is a reliable prognostic indicator of survival and disease
recurrence (Kalnins et al, 1977; Schuller et al, 1980; Snow et al,
1982; Grandi et al, 1985). In addition to nodal metastasis,
extracapsular spread (ECS) of lymph node metastasis is signifi-
cantly associated with a further increase in loco-regional
recurrence and distant metastasis, further reducing the overall
survival (OS) rate of patients with this disease (Noguchi et al, 1999;
Prim et al, 1999; Myers et al, 2001; Greenberg et al, 2003; Woolgar
et al, 2003; Wenzel et al, 2004; Larsen et al, 2009). The presence of
ECS is therefore a marker for biologically aggressive disease, and is
the most pivotal predictor of survival, recurrence, and distant
metastasis. Thus, patients who present with ECS require intensi-
fication of multimodality therapy. However, the detection of ECS is
currently performed by histological examination of the dissected
lymph nodes after surgery, making it impracticable to determine
ECS of lymph node metastasis preoperatively. Therefore, to
determine patients with ECS, who would benefit from invasive
treatment, it is necessary to determine the predictive markers that
indicate a high risk of ECS.
Although ECS is frequently present in patients with advanced
nodal metastasis, it is also detected not only in a small number of
patients with early-nodal disease and but also even in those with a
clinically negative (N0) neck (Alvi and Johnson, 1996; Coatesworth
and MacLennan, 2002). This has made prediction of ECS even
more difficult. Improvements in various imaging modalities, such
as computed tomography, magnetic resonance imaging, ultra-
sound, and positron emission tomography have allowed us to
detect lymph node metastasis and ECS preoperatively. However, all
these imaging methods are limited in their ability to detect smaller
tumour volume (Sano and Myers, 2007). The incidence of
micrometastases that cannot be detected by any imaging technique
is as high as 25%, and thus, on the basis of imaging criteria alone,
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sit is still difficult to detect ECS occurring in early-nodal disease or
N0 neck (Connor and Olliff, 2000).
New diagnostic strategies for the prediction of ECS are therefore
urgently required to identify patients with aggressive disease.
Identification of predictive biomarkers that indicate a high risk of
ECS would have a major role in determining the optimal
therapeutic strategy for these aggressive diseases and in achieving
a high survival rate. Unfortunately, however, there are currently no
molecular markers for the detection of ECS in oral squamous cell
carcinomas (OSCCs).
The cyclin D1 gene (CCND1) is a proto-oncogene, located on
chromosome 11q13, that is elevated in response to extracellular
mitogens. It is also a rate-limiting regulator of G1-phase
progression through the cell cycle, and has been shown to be
associated with an increase in lymph node stage in anterior tongue
cancer (Motokura et al, 1991; Sherr, 1995; Bova et al, 1999; Carlos
de Vicente et al, 2002). Since 1998, we have been investigating
alterations in CCND1 using fluorescence in situ hybridisation
(FISH), with fine-needle aspiration (FNA) biopsy samples from
primary OSCCs, and have demonstrated clearly that CCND1
numerical aberrations are significantly associated with an invasive
phenotype and cervical lymph node metastasis in OSCCs
(Miyamoto et al, 2002, 2003; Myo et al, 2005; Uzawa et al, 2007;
Takahashi et al, 2009). These observations suggest that CCND1
might have an important role in the process of metastasis and the
development of ECS.
On the other hand, the epidermal growth factor receptor gene
(EGFR) is a transmembrane tyrosine kinase receptor. Signalling
through this receptor leads to the activation of multiple signalling
proteins that initiate a cascade of several signal pathways,
including the Ras-Raf-mitogen-activated protein kinase pathway,
the phosphatidylinositol 3-kinase-Akt pathway, and the signal
transducer and activators of transcription pathway, all of which are
potent oncogenic regulators of tumour cell growth, invasion,
angiogenesis, and metastasis (Arteaga, 2002; Arany et al, 2003).
Overexpression of EGFR is seen in approximately 80% of HNSCCs,
and has been reported to be of strong prognostic value and to have
a significant association with nodal metastasis (Rubin Grandis
et al, 1998; Xia et al, 1999; Ang et al, 2002; Bei et al, 2004;
Takahashi et al, 2009). However, EGFR overexpression is not
always linked to the gene copy number aberrations (Chung et al,
2006; Egloff and Grandis, 2009). Thus, although our previous
investigation revealed that copy number aberrations of this gene is
one of the most significant prognostic markers in OSCCs
(Takahashi et al, 2009), it is not clear that the association between
EGFR gene copy number status and the presence of ECS. In the
present study, we therefore focused on copy number changes in
these two genes in primary tumours.
There are two aims of the present study. The first is to confirm
the clinical and prognostic significance of the presence of ECS in
OSCCs. The second is to determine the factors significantly
correlated with the presence of ECS. We examine a number of
factors including clinicopathological features of the primary
tumour, lymph node metastasis, and the CCND1 and EGFR gene
status of primary tumours, and evaluate the value of predicting the
risk of ECS of metastatic lymph nodes.
PATIENTS AND METHODS
Patient characteristics
The medical records of 127 consecutive OSCC patients who had
undergone primary surgical excision with curative intent at the
Maxillofacial Surgery, Graduate School, Tokyo Medical and Dental
University (Tokyo, Japan), between June 1999 and April 2008, were
reviewed for this study. No patients had preoperative treatment.
All protocols of this study were reviewed and approved by the
Research Ethics Committee of Tokyo Medical and Dental
University. Informed consent was obtained from all patients in
accordance with our Institutional guidelines. The clinical staging
was defined on the basis of the International Union Against Cancer
TNM classification (Sobin et al, 2009). The primary tumours were
classified histopathologically as well-, moderately, or poorly
differentiated according to the level of differentiation defined in
the World Health Organization classification (World Health
Organization, 1998). The mode of tumour invasion was also
classified using a modification of the criteria of Jacobsson et al
(Jacobsson et al, 1973; Yamamoto et al, 1983). Histological data
obtained from neck dissection specimens included the number of
positive nodes and the presence or absence of ECS. Extracapsular
spread was defined as extension of the tumour through the capsule
of the lymph node into the perinodal tissues. The presence of
tumour cells in the capsule of the node was not considered ECS.
Fine-needle aspiration–fluorescence in situ hybridisation
analysis
To investigate the genetic status of the primary tumour, FISH
analysis was performed. Samples were taken from 127 primary
tumours by FNA technique, and FISH assays were performed as
described previously using two types of BAC clone probes, specific
for CCND1 and EGFR (Vysis, Downers Grove, IL, USA), labelled
with Spectrum Orange, and chromosome 11 and 7 centromeric
DNA, labelled with Spectrum Green (Miyamoto et al, 2002).
Samples were grouped as follows: balanced disomy, chromosome/
nucleus ratio (C/N) p2.5; balanced trisomy, C/N 26–3.0; balanced
polysomy, C/N 43.0 (in which balanced patterns had an average
ratio gene/chromosome copy number per nucleus (G/C) of
0.9–1.2); and amplification, G/C 41.2 and gene/nucleus ratio
43.0 (Sunpaweravong et al, 2005; Takahashi et al, 2009). Tumours
showing disomy were considered normal, with all other tumours
being considered to have gene numerical aberrations.
Statistical analysis
Disease-free survival (DFS) and OS rates were estimated using the
Kaplan–Meier method and statistical significance was determined
using the log-rank test. Disease-free survival time was defined as
the interval between the date of first visit and the date of the
development of local, regional recurrence, and distant metastasis
after surgery. Overall survival time was also calculated from the
date of initial examination to the date of death, or to the date of the
5-year follow-up. Multivariate DFS and OS analyses were
performed using the Cox proportional hazards model. Multivariate
analysis for ECS risk factors was performed using the logistic
regression analysis. The level of significance was set at Po0.05. All
statistical analyses were performed using SPSS for Windows
(version 17.0, SPSS, Inc., Chicago, IL, USA).
RESULTS
Demographic data
A total of 127 patients (86 men (67. 7%); mean age 60.2 years; age
range 20–89 years) were included in this study. The median
follow-up period was 43.2 months (range 6.0–60 months).
Tumour characteristics and staging
The sites of the primary tumours were derived from tongue
(n¼77), lower gingiva (n¼27), floor of the mouth (n¼10), upper
gingiva (n¼4), and the buccal mucosa (n¼9). A total of 41 of the
127 patients (32.3%) had T1 tumours, 61 (48.0%) had T2 tumours,
12 (9.5%) had T3 tumours, and 13 (10.2%) had T4 tumours at the
time of presentation. The growth pattern of the primary tumour
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swas classified as superficial (n¼27), exophytic (n¼43), and
endophytic (n¼57). A total of 74 of the 127 patients (58.3%) had a
N0 node, 21 (16.5%) patients had a pathologically positive node
without ECS (pNþ/ECS ), and 32 (25.2%) patients had a
pathologically positive node with ECS (pNþ/ECSþ).
Impact of extracapsular spread on survival
To assess the impact of ECS on survival, the survival data of the
patients were compared between the three groups, N0, pNþ/
ECS , and pNþ/ECSþ. Kaplan–Meier survival curves for DFS
and OS are presented in Figures 1A and B, respectively. Disease-
free survival rates for 5 years are 86.5% for N0, 90.5% for
pNþ/ECS , and 40.1% for pNþ/ECSþ patients. Overall survival
rates for 5 years are 89.1% for N0, 90.2% for pNþ/ECS , and
45.1% for pNþ/ECSþ patients. These results clearly demonstrate
the adverse impact of group pNþ/ECSþ compared with groups
N0 and pNþ/ECS  on both disease recurrence (log-rank test.
Po0.0001 and Po0.0001) and OS (log-rank test. Po0.0001
and P¼0.001). Multivariate Cox proportional hazards analysis
revealed that smoking habit, pathological T stage, cellular
differentiation, and presence of ECS were independently signi-
ficant in predicting DFS (Table 1). With regard to OS, the
pathological T stage and presence of ECS retained a statistically
significant prognostic value (Table 1). Therefore, pathological
T stage and presence of ECS are significant independent predictors
in both DFS and OS.
Associations with extracapsular spread
The correlations between presence of ECS and clinicopathological
parameters in the OSCC patients are summarised in Table 2. There
were no significant associations between presence of ECS and age,
smoking habit, tumour site, growth pattern, pathological T stage,
and cellular differentiation. In contrast, the presence of ECS was
significantly correlated with the number of pathologically positive
nodes (P¼0.001), indicating that ECS is more frequent in patients
with multiple positive nodes. With regard to the size of the
metastatic lymph node, although the presence of ECS occurred
more frequently in large nodes at both the minor and major axis
compared with small metastatic lymph nodes, these differences
were not statistically significant. On the other hand, the presence
of CCND1 and EGFR numerical aberrations of the primary tumour
was significantly associated with the presence of ECS in metastatic
lymph nodes (P¼0.011 and 0.004, respectively). A multivariate
logistic regression analysis, including clinicopathological factors,
lymph node metastasis, and genetic status of the primary tumour,
revealed that only the number of pathologically positive lymph
nodes and the presence of EGFR numerical aberrations of the
primary tumour were significantly independent predictors of
ECS (odds ratio¼9.400 and 8.206, 95% confidence interval¼
2.136–41.370, and 1.631–41.295, P¼0.003 and P¼0.011, respec-
tively, hit ratio¼73.1%; Table 3).
DISCUSSION
For HNSCCs, including oral cancer, ECS has been shown to be a
significant predictor of treatment outcome. Myers et al (2001)
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Figure 1 (A) Kaplan–Meier curve for disease-free survival according to
lymph node status. (B) Kaplan–Meier curve for overall survival according
to lymph node status.
Table 1 Independent prognosis factors in multivariate Cox proportional hazards analysis
Disease-free survival Overall survival
Variables P-value HR 95% CI P-value HR 95% CI
Age NS — — NS — —
Gender NS — — NS — —
Alcohol habit NS — — NS — —
Smoking habit 0.0070 3.365 1.387–8.165 NS — —
Pathological T stage 0.0001 5.505 2.417–12.540 0.0001 4.574 2.006–10.429
Cellular differentiation 0.0380 2.448 1.051–5.701 NS — —
Mode of invasion NS — — NS — —
pN NS — — NS — —
ECS 0.0001 7.345 3.269–16.501 0.0001 5.986 2.460–14.566
CCND1 numerical aberration NS — — NS — —
EGFR numerical aberration NS — — NS — —
Abbreviations: CI¼confidence interval; ECS¼extracapsular spread; EGFR¼epidermal growth factor receptor gene; HR¼hazard ratio; NS¼not significant; pN¼pathologically
positive node.
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sreviewed 266 patients with SCC of the tongue and determined a
5-year disease-specific survival rate of 88% for pN0 patients, 65%
for patients with intranodal lymph node metastases, and 48% for
patients with extranodal lymph node metastases. Wenzel et al
(2004) also showed that OSCC patients with no positive nodes or
positive nodes without ECS had nearly the same 5-year rates for
being free from distant metastases (79, 82%), local recurrence
(61, 67%), neck recurrence (84, 87%), and survival (67, 59%),
whereas those with ECS had 1.5–2 times worse rates for every
clinical parameter. Shingaki et al (1999) reported a 5-year disease-
specific survival rate of 40% with and 72% without ECS for patients
with oral cancer. In the current study, we also clearly demonstrated
the adverse impact of group pNþ/ECSþ compared with groups
N0 and pNþ/ECS  on both disease recurrence and OS. Moreover,
multivariate Cox proportional hazard analysis revealed that
pathological T stage and presence of ECS is significantly correlated
with disease recurrence and survival. These findings are in keeping
with the previous observations that ECS is a discriminatory and
significant predictor for prognosis of patients with HNSCCs
(Noguchi et al, 1999; Prim et al, 1999; Shingaki et al, 1999; Myers
et al, 2001; Greenberg et al, 2003; Woolgar et al, 2003; Wenzel et al,
2004; Larsen et al, 2009).
Of first interest in this study was that multivariate analysis
indicated the presence of ECS rather than the existence of a
metastatic lymph node as a significant predictor of disease
recurrence and poor prognosis. Rather than indicating the
difference between N0 and Nþ, these findings show that
differentiation between intra- and extra-capsular spread of the
lymph node contains the essential discriminatory power. Recently,
Shaw et al (2010) reviewed 400 OSCC patients, and reported a
5-year OS rate in ECS-positive patients of 23% compared with 52%
in pNþ/ECS  patients and with 65% in pN0 patients. They also
found differences in survival curves to be highly significant
between pN0, pNþ/ECS , and pNþ/ECSþ (Po0.001, log-rank
test). These findings are in accord with our results, indicating that
the presence of ECS is a more significant predictor of recurrence
and survival than the presence of cervical lymph node metastasis.
However, at present, the existence of ECS can only be clarified
after neck surgery, thus preventing preoperative determination.
Moreover, as a significant number of ECS are detected in early-
nodal disease and even in patients with N0 neck, recent imaging
modalities are unable to detect ECS before surgery (Alvi and
Johnson, 1996; Connor and Olliff, 2000; Coatesworth and
MacLennan, 2002; Sano and Myers, 2007). Therefore, it is
necessary to determine the predictive markers that indicate a high
risk of ECS. Thus, in this study, we attempted to determine
significant factors related to ECS: multivariate logistic regression
analysis revealed that number of pathologically positive lymph
nodes and presence of EGFR numerical aberrations of the primary
tumour were significantly independent predictors.
ECS is histopathologically documented in approximately 60% of
patients with cervical metastases, and is generally thought to be
related to nodal size (Coatesworth and MacLennan, 2002).
However, although ECS has been detected in 60–100% of lymph
nodes 43cm in diameter, it has also been shown in 39–59% of
nodes o3cm and in 23% of nodes o1cm (Puri et al, 2003).
Moreover, ECS has been determined in patients with N0 neck,
whereas the incident rate of ECS in those with N0 neck is between
13 and 60% (Cole and Hughes, 1997). In this study, we investigated
the association between presence of ECS and metastatic lymph
node size, and determined that although ECS occurs more
frequently in larger-sized nodes, in both the minor and major
axis, compared with small nodes; but these differences were not
statistically significant. This finding is compatible with the
Table 2 Univariate analysis of potential predictors of ECS
Clinicopathologic parameters N *
pN+
ECS **
pN+
ECS+*** P-value
a
Gender
Male 45 14 27 0.023
b
Female 29 7 5
Age (years)
p60 35 10 15 NS
460 39 11 17
Alcohol habit
( ) 38 8 10 0.005
b
(+) 33 13 21
Smoking habit
( )3 9 1 2 1 1 N S
(+) 32 9 20
Tumor site
Tongue 45 13 19 NS
Lower gingiva 18 4 5
Floor of mouth 3 2 5
Upper gingiva 2 1 1
Buccal mucosa 6 1 2
Growth pattern
Superficial 18 3 6 NS
Exophytic 28 8 7
Endophytic 28 10 19
Pathological T stage
1–2 65 14 23 0.042
c
3–4 9 7 9
Cellular differentiation
Well/moderate 64 19 24 NS
Poor 10 2 8
Mode of invasion
1–3 53 13 14 0.009
b
4C–D 21 8 18
Number of positive nodes
d
1 — 13 5 0.001
e
X2— 8 2 7
Size of positive nodes
f (mm)
Minor axis (3–20)
p10 — 13 16 NS
410 — 8 16
Major axis (5–27)
p14 — 14 14 NS
414 — 7 18
Gene status in primary tumor
CCND1 numerical aberration
( ) 56 16 12 0.0001
b
(+) 18 5 20 0.011
e
EGFR numerical aberration
( ) 51 18 14 0.018
b
(+) 23 3 18 0.004
e
Abbreviations: ECS¼extracapsular spread; EGFR¼epidermal growth factor recep-
tor gene; NS¼not significant.
aThe P-value was determined using the two-tailed
Fisher exact test.
b* vs ***.
c* vs **.
dDetermined according to histopathological
diagnosis.
e** vs ***.
fDetected by computed tomography.
Table 3 Independent predictors of ECS in multivariate logistic regression
analysis
Variables OR 95% CI P-value
Age — — NS
Gender — — NS
Alcohol habit — — NS
Smoking habit — — NS
Pathological T stage — — NS
Cellular differentiation — — NS
Mode of invasion — — NS
Number of positive nodes 9.400 2.136–41.370 0.003
CCND1 numerical aberration — — NS
EGFR numerical aberration 8.206 1.631–41.295 0.011
Abbreviations: CI¼confidence interval; ECS¼extracapsular spread; NS¼not
significant; OR¼odds ratio.
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sprevious observations (Cole and Hughes, 1997; Puri et al, 2003).
Taken together, these findings suggest that ECS can occur in
several ways. Puri et al (2003) recently speculated that in larger
nodes, mechanical disruption, as a result of an expanding tumour
mass, is the main cause of ECS. On the other hand, in smaller
nodes, ECS might result from tumour emboli, lodged in the
capsular sinuses, or by focal destruction of capsular collagen by
collagenase produced by the tumour cells. However, these
processes remain to be elucidated, and further investigation is
warranted.
Several reports have documented the clinicopathological factors
significantly correlated with ECS. Recently, Imre et al (2008)
retrospectively studied 186 patients with laryngeal and hypo-
pharyngeal cancer and, using multivariate analysis, documented
that only number of (43) lymph node metastases was a significant
independent predictor of ECS. More recently, also by means of
multivariate analysis, Shaw et al (2010) examined 400 patients with
OSCCs and demonstrated that age 475 years, smoking, and heavy
use of alcohol were independent predictors of ECS. Furthermore,
Woolgar et al (2003), using univariate analysis, investigated 173
OSCC patients and found that many clinicopathological para-
meters, including gender, age, status of the resection margin,
number of positive nodes, largest metastatic deposit, highest
anatomical level of involvement, and pathological N stage, were
significantly correlated with ECS. In the present study, we
retrospectively examined 127 patients with OSCCs and multi-
variate analysis revealed that number of pathologically positive
lymph nodes and presence of EGFR numerical aberrations at the
primary tumours were significantly associated with ECS. The
number of positive lymph nodes was shown to have a correlation
in the abovementioned reports, suggesting it can be used in the
prediction of ECS. However, the number of pathologically positive
nodes is determined after surgery, and it is therefore impracticable
to obtain this information preoperatively. Therefore, it is not
useful for preoperative selection of patients at high risk of ECS.
On the contrary, second but most interesting and important
finding of this study was that ECS in the metastatic lymph node is
significantly associated with EGFR numerical aberrations at the
primary tumours. This finding suggests that patients at high risk of
ECS could be preoperatively determined by examining EGFR copy
number changes in primary tumours by means of FISH. Although
there are several reports (Chen et al, 2003; Zhou et al, 2006; Huang
et al, 2009) that showed the protein or mRNA overexpression of
EGFR significantly correlated with ECS in the OSCCs, this is the
first study investigating the association between EGFR gene copy
number at the primary tumour and the presence of ECS in the
metastatic lymph node, and clearly demonstrating the significant
correlation between them. Generally, the association between
EGFR FISH status and protein or mRNA expression level still
remains to be concluded (Chung et al, 2006; Egloff and Grandis,
2009). Thus, EGFR gene copy number aberrations have not always
linked to overxepression of this mRNA or protein. Therefore, at
present, the significant association between EGFR FISH status and
ECS might not be related with EGFR alone. FISH-positive status
may be a surrogate marker of generalised genetic instability in the
tumour or of additional genes that are co-amplified with EGFR.
However, how these mechanisms contribute to the occurrence of
ECS remains unclear. Further investigations are required.
In conclusion, the present study clearly demonstrated that ESC
is an independent prognostic factor of OSCCs. Moreover, number
of pathologically positive lymph nodes and EGFR numerical
aberrations of the primary tumours were also shown to be
excellent predictors of ECS in OSCCs. Especially, copy number
changes of the EGFR in the primary tumours were indicated as
clinically useful for selection of patients at high risk of ECS who
would benefit from targeted aggressive multimodality therapy.
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